Earli is pioneering a novel approach to cancer detection and treatment through the development of programmable genetic constructs that specifically activate within cancer cells. These constructs enable the cancer cells to act as "factories," producing signal proteins that can be utilized for diagnostic imaging or to stimulate the immune system against the tumor. This targeted mechanism aims to differentiate between malignant and normal cells, addressing the significant challenge of accurately diagnosing cancer at its earliest stages. Earli's technology has shown promising results in pre-clinical studies, particularly in lung cancer, and is expanding its applications to liver cancer and other therapeutic areas.

The implications of Earli's technology are profound, as it has the potential to transform unclear cancer screening results into definitive diagnoses, allowing for immediate treatment and significantly reducing the risk of metastasis. By preventing the recurrence of cancer, which affects a substantial percentage of lung cancer patients, Earli's innovations could dramatically improve survival rates. The company is committed to advancing early cancer detection and treatment, with ongoing research and development efforts aimed at harnessing the power of synthetic biomarkers and multi-omics analysis to enhance diagnostic accuracy and therapeutic outcomes.

United States

Earli mission is to make cancer a benign experience. 


Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. 

Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.

Earli

Company Details